Hamilton Health Sciences used exosomes, cell derived particles that carry healing signals, on 18 year old Kaitlin Jeffrey, the first human burn patient ever treated with the therapy, under a compassionate use pathway.
Kaitlin Jeffrey, 18, survived a December house fire in London, Ontario, with severe facial burns and avoided the skin-graft surgery that is the standard last resort for such injuries. The treatment that made that possible was exosomes, cell-derived particles that carry healing signals between cells, grown in a lab and injected into injured tissue to accelerate repair.
It was the first time exosome therapy had been used on a human burn patient, according to a Hamilton Health Sciences announcement distributed on June 15, 2026. It was also a single case, treated under a compassionate-use pathway, with no controlled trial, no independent efficacy data, and an informal comparison to another burn victim from the same fire that is not clinical evidence.
Jeffrey, a Western University student from Toronto, was treated at HHS by the hospital's burn program, led by Dr. Marc Jeschke, a burn surgeon who is also the medical director of the regional burn program. Her burns were severe enough that the team wanted to avoid grafting on her face and neck at almost any cost, because grafting can leave scarring and a patch-like appearance that is particularly disfiguring on facial skin. The exosome treatment involved two injections several days apart, delivering roughly one trillion particles in total.
Exosomes have been studied in burn research for years in animals and small human studies, and human exosome clinical trials exist for other wound-healing indications with promising results. What is new is delivering the therapy to a human burn patient outside a trial, and that difference matters for how the result should be read.
HHS reports that Jeffrey healed faster and with a better cosmetic outcome than another young student from the same fire whose burns were serious but not as severe and who was treated with standard care. The comparison is suggestive. It is also a comparison between two patients who differ in injury severity, in treatment, and almost certainly in the underlying biology of their wounds, and it was generated inside the same hospital program that administered the experimental therapy. It cannot tell readers whether exosomes work for severe facial burns in general.
The pathway that made the treatment possible is the relevant context. Under Health Canada's compassionate-use rules, a physician can apply to treat a single patient with an unapproved therapy when standard options are inadequate. HHS submitted an urgent application, and Health Canada responded with a no-objection letter. The exosomes themselves were sourced from lab-grown cells, though the hospital's release does not name the manufacturer or describe the production process, and the public text is truncated where those details would normally appear.
That combination is the part of the story that can be repeated: a well-resourced burn center with an active research program, a clinician willing to file a compassionate-use application, and a regulator willing to issue a no-objection response quickly enough to make treatment possible inside the relevant clinical window. The patient outcome is real, and for Jeffrey the result is the result. For the broader claim that exosomes heal severe facial burns, the evidence is one patient, and one informal comparison that is not a control.
A controlled trial would need to enroll enough patients with comparable severe facial burns to detect a difference from standard care, randomize or otherwise match them, follow them long enough to measure scarring and functional recovery, and ideally test dose, timing, and exosome source as variables. None of that exists yet, and HHS has not announced when it might.
The forward question is whether other burn centers can replicate the pathway, not just the result. If the answer is yes, and a trial follows, a single case in Hamilton becomes the opening move in a real evidence base. If the answer is no, the case remains a documented first that proves a mechanism can be tried on a human burn patient, and a reminder that one patient, however good the outcome, is not yet a treatment.